[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"de01f4b4-b380-45e4-a05f-0573156a9b1c","acronym":"AAML1031","url":"https://clinicaltrials.gov/study/NCT01371981","created_at":"2021-01-18T05:37:13.447Z","updated_at":"2025-02-25T16:51:07.072Z","phase":"Phase 3","brief_title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01371981 - AAML1031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1645","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-04"},{"id":"8ec351f2-1bd5-4f00-9a41-65c5a39f754f","acronym":"HTLP-ONCO","url":"https://clinicaltrials.gov/study/NCT04707300","created_at":"2021-01-19T20:51:47.092Z","updated_at":"2025-02-25T17:00:53.937Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO)","source_id_and_acronym":"NCT04707300 - HTLP-ONCO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HLA-DRB1 • CD34 • CD4 • CD7","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["HLA-DRB1 • CD34 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 102"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/16/2022","start_date":" 02/16/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-03"},{"id":"b4e91c3d-4887-4ce6-b858-890536bcbb7b","acronym":"HOVON 156 AML","url":"https://clinicaltrials.gov/study/NCT04027309","created_at":"2021-01-18T19:46:07.637Z","updated_at":"2025-02-25T15:26:07.674Z","phase":"Phase 3","brief_title":"A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT04027309 - HOVON 156 AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 777","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 06/01/2033","study_completion_date":" 06/01/2033","last_update_posted":"2024-12-17"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"55079916-4788-41a0-a5ca-a4084d122a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024552","created_at":"2021-08-27T12:52:57.710Z","updated_at":"2024-07-02T16:34:26.210Z","phase":"Phase 1","brief_title":"Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML","source_id_and_acronym":"NCT05024552","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-13"},{"id":"3d3f57b8-7c54-40f3-80db-21c1598bb35e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02310321","created_at":"2021-01-18T10:56:18.517Z","updated_at":"2024-07-02T16:34:37.261Z","phase":"Phase 1/2","brief_title":"A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02310321","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 02/26/2015","start_date":" 02/26/2015","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-06-07"},{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"e50a0a5e-dc78-4e71-99c4-1a70effa128a","acronym":"APAL2020D","url":"https://clinicaltrials.gov/study/NCT05183035","created_at":"2022-01-10T14:58:22.318Z","updated_at":"2024-07-02T16:34:59.534Z","phase":"Phase 3","brief_title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05183035 - APAL2020D","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Mylotarg (gemtuzumab ozogamicin) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2024-06-03"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"f66040f9-40e2-41bd-8c69-4d4ef3afbdf1","acronym":"COMMODORE","url":"https://clinicaltrials.gov/study/NCT03182244","created_at":"2021-01-18T15:41:35.073Z","updated_at":"2024-07-02T16:35:01.009Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation","source_id_and_acronym":"NCT03182244 - COMMODORE","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 01/15/2018","start_date":" 01/15/2018","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-24"},{"id":"7b7c91a6-9486-4633-b3e2-ffef9fa008f4","acronym":"ADMIRAL","url":"https://clinicaltrials.gov/study/NCT02421939","created_at":"2021-01-17T17:23:13.438Z","updated_at":"2024-07-02T16:35:01.814Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","source_id_and_acronym":"NCT02421939 - ADMIRAL","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 10/20/2015","start_date":" 10/20/2015","primary_txt":" Primary completion: 09/17/2018","primary_completion_date":" 09/17/2018","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-23"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"fe2e9c02-b568-4273-9f6b-89146f4af44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756962","created_at":"2021-01-18T13:30:57.647Z","updated_at":"2024-07-02T16:35:12.037Z","phase":"Phase 2","brief_title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","source_id_and_acronym":"NCT02756962","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation","tags":["FLT3 • NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/06/2016","start_date":" 07/06/2016","primary_txt":" Primary completion: 07/31/2033","primary_completion_date":" 07/31/2033","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2024-04-02"},{"id":"65ca92b9-439f-4528-a70b-00eb71d74d63","acronym":"GOSSAMER","url":"https://clinicaltrials.gov/study/NCT02927262","created_at":"2021-01-18T14:22:42.677Z","updated_at":"2024-07-02T16:35:14.396Z","phase":"Phase 2","brief_title":"A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission","source_id_and_acronym":"NCT02927262 - GOSSAMER","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 01/10/2017","start_date":" 01/10/2017","primary_txt":" Primary completion: 05/25/2021","primary_completion_date":" 05/25/2021","study_txt":" Completion: 02/19/2024","study_completion_date":" 02/19/2024","last_update_posted":"2024-03-15"},{"id":"79eadd39-4040-4c6b-8888-5e8312df7fad","acronym":"MORPHO","url":"https://clinicaltrials.gov/study/NCT02997202","created_at":"2021-01-18T14:44:39.332Z","updated_at":"2024-07-02T16:35:14.662Z","phase":"Phase 3","brief_title":"A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02997202 - MORPHO","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib)"],"overall_status":"Completed","enrollment":" Enrollment 356","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 05/09/2023","study_completion_date":" 05/09/2023","last_update_posted":"2024-03-15"},{"id":"7e180e9a-1ded-4851-881d-ffda6c389c90","acronym":"NCI-2019-04959","url":"https://clinicaltrials.gov/study/NCT04140487","created_at":"2021-01-18T20:12:57.909Z","updated_at":"2024-07-02T16:35:14.512Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm","source_id_and_acronym":"NCT04140487 - NCI-2019-04959","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-15"},{"id":"31616735-d05c-4ef1-aaeb-a7a574fd21c5","acronym":"PrE0905","url":"https://clinicaltrials.gov/study/NCT03836209","created_at":"2021-01-18T18:56:25.257Z","updated_at":"2025-02-25T15:26:01.620Z","phase":"Phase 2","brief_title":"Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03836209 - PrE0905","lead_sponsor":"PrECOG, LLC.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • midostaurin • daunorubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 10/17/2023","primary_completion_date":" 10/17/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-22"},{"id":"c372b4b4-4bc4-4fd8-9862-9add8d9bb685","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922100","created_at":"2021-01-18T19:17:47.256Z","updated_at":"2024-07-02T16:35:18.417Z","phase":"Phase 1/2","brief_title":"Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML","source_id_and_acronym":"NCT03922100","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NMS-088"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-21"}]